News Announcement

Shukra Pharmaceuticals: Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company Held On Monday July 14 2026 For Confirmation Of Receipt Of The Differential Upfront Consideration From The Allottees Pursuant To Regulation 170(2) Of The SEBI (ICDR) Regulations 2018

The Board took on record and confirmed that in accordance with the terms of the aforesaid Special Resolution and the applicable provisions of Chapter V of the SEBI ICDR Regulations the allottees were required to bring in the differential upfront amount of Rs. 0.39 per Warrant (aggregating to Rs. 18 10 770/-) being the additional amount payable on the upfront 25% (Twenty-Five Per Cent) consideration on account of the re-computation of the issue price from Rs. 34.00 to Rs. 35.56 per Warrant within fifteen (15) days from the date of passing of the Special Resolution. Further Two Allottees have also paid the balance 75% (Seventy-Five Per Cent) of the Warrant Issue Price of differential consideration on or before July 13 2026.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.